Q3 2019 13F Holders as of 9/30/2019
-
Type / Class
-
Equity / American depositary shares, each representing one equity share
-
Shares outstanding
-
835M
-
Number of holders
-
146
-
Total 13F shares, excl. options
-
21M
-
Shares change
-
-715K
-
Total reported value, excl. options
-
$795M
-
Value change
-
-$26.2M
-
Put/Call ratio
-
0
-
Number of buys
-
63
-
Number of sells
-
-64
-
Price
-
$37.89
Significant Holders of DR REDDYS LABORATORIES LTD - American depositary shares, each representing one equity share (RDY) as of Q3 2019
164 filings reported holding RDY - DR REDDYS LABORATORIES LTD - American depositary shares, each representing one equity share as of Q3 2019.
DR REDDYS LABORATORIES LTD - American depositary shares, each representing one equity share (RDY) has 146 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 21M shares
of 835M outstanding shares and own 2.51% of the company stock.
Largest 10 shareholders include ROYAL BANK OF CANADA (4.35M shares), BlackRock Inc. (1.72M shares), RENAISSANCE TECHNOLOGIES LLC (1.48M shares), VANGUARD GROUP INC (1.09M shares), DIMENSIONAL FUND ADVISORS LP (951K shares), WELLINGTON MANAGEMENT GROUP LLP (914K shares), GOLDMAN SACHS GROUP INC (627K shares), Parametric Portfolio Associates LLC (599K shares), Aperio Group, LLC (597K shares), and Mondrian Investment Partners LTD (552K shares).
This table shows the top 146 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.